Background: Hepatitis B virus (HBV) infection remains a global concern with different epidemiologies due to several factors including migration, vaccination policies, and new antiviral treatment regimens. It is important to understand the characteristics of a patient population, including the prevalence of diseases, and to assess test utilization to understand and evaluate the clinical performance of laboratory tests and to improve the quality of clinical laboratories.
| INTRODUC TI ON
Hepatitis B virus (HBV) infection remains a global concern with different epidemiologies due to several factors including migration, vaccination policies, and new antiviral treatment regimens. 1 In Korea, the prevalence of HBV carriers has changed from 8-10% in the 1980s and early 1990s to 2.9% in 2013. 2 Multiple serologic and virologic tests for HBV infection are usually performed simultaneously. 1, 3 Hepatitis B surface antigen (HBsAg) is an envelope protein of HBV detectable in the blood in HBV infection. 3 HBV surface antibody (anti-HBs) is an antibody to HBsAg and develops during recovery from hepatitis B and in response to hepatitis B vaccination indicating past infection and immunity. 3 Hepatitis B envelope antigen (HBeAg) is a marker of viral replication indicating a highly infectious virus. 1 HBV envelope antibody (anti-HBe) is an antibody to HBeAg detectable in persons with lower levels of HBV replication. 3 HBV DNA can be detected and quantified in serum. 1 Combinations of different positive and negative results of these various tests are used for diagnosis, monitoring of HBV infection, and evaluating treatment responses. 1, 4 Physicians can have difficulties in interpreting laboratory results with different combination of positives and negatives when they do not understand the patient population and their result patterns. 3, 5 It is important to understand the characteristics of a patient population, including the prevalence of diseases, to understand and evaluate the clinical performance of laboratory tests, and to improve the quality of clinical laboratories. 5 Meanwhile, in the past decade, there has been a lot of studies for the use of serum HBsAg quantification to assess disease activity and monitor treatment response in chronic hepatitis B. 1, 6 Currently, HBsAg test is widely recommended due to the development of new therapies to achieve HBsAg seroclearance indicating functional cure of hepatitis B. 2 To improve patient outcomes, laboratory tests must be ordered and interpreted appropriately. 7 Although there have been several studies of serologic and virologic laboratory analyses for HBV, they usually focused on HBsAg seroprevalence, treatment responses, or patient risk for hepatocellular carcinoma. 6, 8 Few studies have involved comprehensive analysis of laboratory results for HBV test utilization. Green Cross Laboratories is one of the largest referral clinical laboratories in Korea, and they administer various laboratory tests for hepatitis B in 514 private clinics nationwide.
Therefore, the aim of this study was to provide information about test result prevalence for different combinations of HBV tests to help physicians and clinical laboratory professionals understand patient population characteristics in Korea by evaluating serologic and virologic laboratory test results of HBsAg, anti-HBs, HBeAg, anti-HBe, and HBV DNA in Korean adults exposed to HBV. Furthermore, we investigated the test utilization of those HBV tests in our laboratory, one of the largest referral clinical laboratories in South Korea.
| MATERIAL S AND ME THODS

| Study populations
Data for laboratory test results were obtained through the labora- Green Cross Laboratories is a referral laboratory with limited access to clinical information, samples that were simultaneously tested with for serum anti-HBe, HBeAg, and HBV DNA real-time PCR tests were regarded as originating from individuals who were exposed to HBV. 1, 4, 9, 10 The laboratory results for HBsAg and anti-HBs tests of those samples were also reviewed. All data were anonymized before analysis. This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Institutional Review Board of Green Cross Laboratories (GCL-2018-1007-03). 
| Analytical procedures
| Statistical analysis
| RE SULTS
| D ISCUSS I ON
In this study, we evaluated 22 750 specimens from 17 523 adults regarded as having chronic HBV infection during the study period. HBV blood test results can be challenging for physicians to interpret because the complex biological and clinical implications of various HBV tests depend on patient immune response. [11] [12] [13] Atypical serologic profiles have puzzled virologists and clinicians since the late 1970s. 12 Although Green Cross Laboratories was limited in terms of clinical information, evaluation of requested test items could be used to make assumptions about the patient population based on the knowledge that the HBeAg, anti-HBe, and HBV DNA test were performed for patients exposed to HBV in Korea. 4 Although HBV DNA level and HBeAg S/CO values were significantly associated, their results were discrepant for more than half the specimens (695/1,340, 51.9%).
Because HBeAg is not essential for viral replication and the HBeAg loss or seroclearance rate varies according to viral DNA replication, both tests are recommended to be performed simultaneously to monitor chronic HBV infection. 1, 3, 10, 14 According to recommendations from the 2015 and 2018 Korean 1, 7 The results indicated that co-expression of HBsAg and anti-HBs occurred in 2.1% (28/1340) of this study population. Co-expression of HBsAg and anti-HBs has been hypothesized to result from primary infection with multiple subtypes followed by clearance of one, from viral strains carrying HBsAg mutations that escape anti-HBs neutralization, or from change in the primary sequence of the ''a'' determinant in the S gene region of HBV that alters its antigenic structure. 12 However, the clinical significance of many mutations on HBsAg antigenicity still remains to be clarified. 6, 7, 12 Because the clinical significance of patients with those test results should be further studied and improved in accordance with various treatment regimens, it is important to know about the prevalence change. 12, 16 The limitation of this study was the lack of clinical information including detailed history and physical examination and other laboratory and image studies associated with HBV infection and disease 
